Gunderson Dettmer represented client Section 32 on the deal while Wilson Sonsini advised BigHat Biosciences. Section 32, a venture capital fund that invests in frontiers of...
You must be a Standard 1 Year member to access this content.
Wilson Sonsini Goodrich & Rosati advised Verve Therapeutics on the deal. Verve Therapeutics, a biotechnology company pioneering a new approach to the care of cardiovascular disease...
You must be a Standard 1 Year member to access this content.
Wilson Sonsini advised Faeth Therapeutics on the deal. Faeth Therapeutics, a cancer metabolism company, announced the completion of a Series A financing of $47 million led...
You must be a Standard 1 Year member to access this content.
Wilson Sonsini Goodrich & Rosati represented ReCode Therapeutics in the transaction. ReCode Therapeutics, a genetic medicines company using superior delivery to power the next wave of...
You must be a Standard 1 Year member to access this content.
Wilson Sonsini Goodrich & Rosati represented Mirvie on the deal. Mirvie, a pioneer in predicting unexpected pregnancy complications, announced it has raised $60 million in a...
You must be a Standard 1 Year member to access this content.
Wilson Sonsini advised VitroLabs on the deal. VitroLabs Inc, a Bay-Area-based biotech company leading the development of a new scientific process to grow the world’s first...
You must be a Standard 1 Year member to access this content.
Latham & Watkins and Wilson Sonsini represented Affini-T Therapeutics, Inc. in the transaction. Affini-T Therapeutics, Inc., a biotechnology company unlocking the power of T cells against oncogenic...
You must be a Standard 1 Year member to access this content.
Wilson Sonsini Goodrich & Rosati advised Cellino on the deal. Cellino Biotech, an autonomous cell therapy manufacturing company, announced the completion of a Series A financing...
You must be a Standard 1 Year member to access this content.
Goodwin Procter advised Acadia Pharmaceutical on the deal while Wilson Sonsini represented Stoke Therapeutics. Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) announced its collaboration agreement with Stoke Therapeutics, Inc....
You must be a Standard 1 Year member to access this content.
Wilson Sonsini Goodrich & Rosati advised NanoCellect on the deal. Microfluidic cell sorting company NanoCellect Biomedical announced the closing of $35 million in Series C and...
You must be a Standard 1 Year member to access this content.
Wilson Sonsini Goodrich & Rosati advised Vida Ventures on the deal while Goodwin Procter represented Vigil Neuroscience. Vigil Neuroscience, a biotechnology company harnessing the power of...
You must be a Standard 1 Year member to access this content.
Wilson Sonsini Goodrich & Rosati advised Verve Therapeutics on the deal. Verve Therapeutics (Nasdaq: VERV), a biotech company pioneering a new approach to the care of...
You must be a Standard 1 Year member to access this content.
